Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
about
Haloperidol dose for the acute phase of schizophreniaNicotine for schizophreniaNicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialNegative affective states and cognitive impairments in nicotine dependenceChronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia.Effects of nicotine on attention and inhibitory control in healthy nonsmokers.Effects of smoking on the acoustic startle response and prepulse inhibition in smokers with and without posttraumatic stress disorderMouse models for studying genetic influences on factors determining smoking cessation success in humans.The effect of withdrawal and intake of nicotine on smokers' ability to ignore distractors in a number parity decision taskNicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorEffects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking statusMolecular targets for treating cognitive dysfunction in schizophrenia.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Haloperidol dose for the acute phase of schizophrenia.Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performancePredictors of early abstinence in smokers with schizophreniaAcute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.The interactive effects of ketamine and nicotine on human cerebral blood flowCo-morbidity of smoking in patients with psychiatric and substance use disorders.Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptorsAssessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophreniaSmoking and schizophrenia independently and additively reduce white matter integrity between striatum and frontal cortex.Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment?Initial phase 2 trial of a nicotinic agonist in schizophrenia.Substance abuse in patients with schizophrenia.Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trialVentral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats.Smoking, Suicidality and Psychosis: A Systematic Meta-Analysis.A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.The effect of α7 nicotinic receptor activation on glutamatergic transmission in the hippocampus.Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits.Insular and anterior cingulate circuits in smokers with schizophrenia.Cholinergic circuits and signaling in the pathophysiology of schizophreniaTreatment of tobacco dependence in mental health and addictive disorders.
P2860
Q24200200-ABF96C0B-ADAE-4DBB-ACB5-E9F81A6A269BQ24244830-0BB03EAE-A8C0-4F1B-B582-4A986C5F30E3Q24532028-323A7CA0-EA0B-45F0-B6FD-7039077EA94FQ24643892-DC663736-AFB7-4051-8A16-6B41F90A2D2DQ28552053-AA5B735A-8CA1-4AB5-B176-FAAAAB249A77Q30371220-A38ED090-081C-4FA0-9BB0-3C931026C707Q30415168-A6048DBF-3478-4374-A829-04E401466FD4Q30422977-37695B1C-70A2-413C-8436-DAF046CD3A60Q30424367-2C4FFCB7-2EA4-4DAE-9361-DC3F2D5E63A9Q30432964-32BB4964-658B-401F-A00D-079711801C8FQ30446776-A9115A6F-BA65-4DED-9DC9-812CB4A6D3A0Q30453198-4A11389E-8A3F-4E52-9C3F-70C7780BFA5AQ30455599-0F8E7771-825D-421D-AC6B-C011B5DFD180Q30478035-62053F51-3616-412C-9B15-BE068AE5FCA0Q30479419-25B0F096-7E6B-493C-A0EB-9932654F9281Q30491310-A382672D-F63E-46DC-A7E4-CFEBFB37EFE4Q30493072-2774C8E2-C07D-4FA6-9184-58C666AE5604Q30838771-1A633713-A98A-4072-A571-E34A5639D409Q33635728-42C3F789-35EE-489B-8217-FDF6EC499F33Q33679772-F73D8C0C-18EA-4F12-9676-382275FD0973Q33768017-34979935-4D17-4A10-A31E-B6187C44E1F9Q33937889-2B91AE56-FA15-4879-8A5B-CF8ED9B42AADQ33942653-C8D905AF-86A5-4E98-BD58-3C37B7F2A917Q34324912-47EEA66D-7445-4C48-89BE-D89D9146838EQ34394895-878C39F4-ED6E-4984-A961-0608166F8AB9Q34502083-3E17729A-7826-4E76-BC1D-7F08DB23E897Q34604413-95D4C320-09C3-4A0A-8152-86B22C25BDB9Q34729934-9ED8CA47-430D-4CEA-99F2-E7695DF5DBF1Q34754314-AF65BD6E-4229-4876-90A7-DD38240D16F1Q34766663-95D8DAE0-1B69-4178-B692-52C809710482Q35236689-41FF2D30-FF93-4BA5-B4B4-FF1187BDFCCCQ35679935-E82673D8-1266-4708-B71E-8902A9878199Q35740911-C1184EE7-D24D-4E40-A1AC-AAF6AC0F55ABQ35776095-8A76095A-512A-4031-95CE-ECEA892A3D66Q35891345-9625D9DD-00B6-4347-A6F7-BFDD912BA929Q36144877-6571D675-BD25-4A91-B31B-06D3A7BADBACQ36363825-78321E00-4804-4CC1-82AE-6EA2EE41186DQ36413030-FBD13474-D1D4-4FBE-9139-7BEA307C9D36Q36756379-326C05C7-0BF6-4171-873D-CC9F33858F07Q36783506-1E134051-F788-47F3-ACD4-FB8306E21A32
P2860
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@en
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@nl
type
label
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@en
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@nl
prefLabel
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@en
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@nl
P2093
P1476
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
@en
P2093
P304
P356
10.1016/S0893-133X(96)00018-8
P407
P577
1996-11-01T00:00:00Z
P6179
1014451375